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Genome integrity is maintained by the concerted
action of distinct DNA repair pathways. DNA
nucleases resolve damaged DNA and unusual DNA
structures that arise during cellular processes such
as replication, recombination, and transcription.
DNA repair nucleases usually recognize aberrant
DNA conformations of damaged and/or potentially
mutagenic DNA intermediates, rather than DNA
sequences; hence, they are referred to as ‘structure-
specific nucleases’. DNA repair machinery corrects
errors incurred during replication in mitotic cells, and
repairs damaged DNA in non-mitotic cells [1]. Pro-
Fig. 1. Genomic region of human FAN1 at 15q13.3 (GRCh37/hg19). (a) Schematic organization of 15q13.3 microduplication/microdeletion
region contains multiple genes including FAN1. (b) FAN1 and MTR10 are partially overlapped and include various coding and non-coding
genetic variants identified in HD, various spinocerebellar ataxias (SCAs), autism (ASD), and schizophrenia (SZC). The murine homolog of
p.S795P (mS798P, in between the TPR and the nuclease domain) was identified in a murine Rett syndrome modifier screen [86]. CAG/polyQ
disease-hastening and disease-delaying variants are shown in red and green fonts, respectively. (c) FAN1 has various transcript variants, a
limited set of full length and truncated FAN1 transcript variants are shown (NM: Transcript variant, NP: Isoforms of transcript variant).
Information for making this figure is from the NCBI genome browser, UCSC genome browser, and Ensembl browser. For details of the
15q13.3 chromosomal rearrangements, see Supplementary Figure 1. (d) Table with HD modifier haplotypes in FAN1.
cessing of aberrant DNA structures, particularly steps
involving nucleolytic cleavage, represents a com-
mitted and tightly controlled biological ‘decision’ in
genome maintenance pathways. If not kept in check,
structure-specific nucleases can cause extensive
DNA degradation and wreak havoc on the stability
of the genome [2]. On the other hand, the essential
nature of structure-specific nucleases is underscored
by the fact that homozygous null mutations in
genes encoding these enzymes are often embryonic
lethal or lead to infertility; single site mutations may
predispose to cancer or other diseases (for review, see
[2]). This review focuses on FAN1, with particular
attention to its potential roles as a modifier of dis-
orders associated with genomic repeat expansions,
including Huntington’s disease (HD), spinocere-
bellar ataxia type 1 (SCA1), SCA2, SCA3, SCA6,
SCA7, SCA17, autism, schizophrenia, and others.
1. FAN1 GENIC REGION AND DISEASE-
ASSOCIATED GENETIC VARIANTS
1.1. Genes
FAN1 (OMIM#613534) was initially identified
as KIAA1018 in a human brain cDNA library and
found to be ubiquitously expressed in the cen-
tral nervous system and peripheral tissues [3]. The
protein encoded by KIAA1018 interacts with the
mismatch repair (MMR) proteins, PMS2 [4] and
MLH1 [4], and FANCD2 [5–8]. Except where
noted, we refer to the gene in question as
FAN1. FAN1, at 15q13.3 (GRCh37/hg19 coordinates:
chr15:31,196,076-31,235,31) contains 15 exons, of
which 13 are coding. The gene’s cis-acting regions
include promoter regions, CpG islands, transcription
factor binding sites, and enhancers (Fig. 1b). It has
three predicted promoters (as per EPD, ENSEMBL,
and NCBI), two of which are located upstream of
exon 1, while the third promoter resides in intron 8. A
large CpG island of 918 base pairs (bp) spans exon1,
promoter 1 and further upstream [9–11] (Fig. 1b).
Various FAN1 variants and the FAN1 haplotypes
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associated with HD and SCAs are shown in Fig. 1
(summarized in 1d) and discussed in detail in Section
6.1 and 6.2.
1.2. Transcripts
FAN1 transcripts are predicted to undergo alter-
native splicing, generating 28 potential transcript
variants (Fig. 1c), which code for full-length or trun-
cated proteins. Some transcripts are predicted to
undergo nonsense-mediated decay, and some retain
introns [11]. A FAN1 splicing effect on HD modifiers
is unlikely, based upon analyses of data in non-disease
expression databases [12]. FAN1/Fan1 circular RNA
(circRNA) was identified in human and mouse heart,
but is of unknown function [13]. The MTMR10 gene
partially overlaps with FAN1 and is convergently tran-
scribed (Fig. 1a,b). Disease onset-modifying variants
in overlapping regions of these two genes have
been identified (Fig. 1). MTMR10-tagging single
nucleotide polymorphisms (SNPs) identified in indi-
viduals with HD or SCA2 may relate to FAN1
expression levels [14–16]. MTMR10 transcripts could
hypothetically act in an antisense manner to regulate
FAN1 mRNA stability and translatability. The same
might be true where a FAN1 transcript regulates the
MTMR10 mRNA. Evidence of such antisense regu-
lation is not known for these genes but could provide
insight into targeting for therapeutic purposes.
1.3. MTMR10 and TRPM1
The 15q13.3 region with adjacent genes, FAN1,
MTMR10, and TRPM1 (Transient Receptor Potential
Melastatin Family member 1) (Fig. 1a), appears to be
enriched with variants that modify HD onset. FAN1
has been referred to as MTMR15 [17]; however no
data reveal any relation of FAN1 to myotubularin-
related proteins (MTMs) [7]. In contrast, MTMR10
is an MTMR family member. Various tagSNPs asso-
ciated with HD age of onset are within or proximal to
the two overlapping convergently transcribed genes,
MTMR10 and FAN1 (Fig. 1b,d). A protein coding
variant in TRPM1 (rs3784588; p.V1434I) is asso-
ciated with hastening HD onset [12]. The roles of
MTMR10 or TRPM1, if any, in HD or any of the
15q13.3-related diseases, are unknown. TRPM1 and
MTMR10 have been argued to not be HD modifiers,
based upon genetic data [14] and the absence of
an effect of the disease-delaying variant haplotype
(15AM2) upon expression levels of either TRPM1
or MTMR10 in non-HD databases [12, 14]. More-
over, genetic ablation of Mtmr10 does not affect CAG
instability in HD mice, whereas ablation of Fan1 does
[18]. The effect of TRPM1/Trpm1 on CAG instability
in human or mouse models has not been addressed.
1.4. 15q13.3 micro-deletion/-duplication,
and CNVs
Genetic variants of FAN1 include copy number
variations (CNVs), inversions, and single nucleotide
variants (SNVs). FAN1 and MTMR10 lie within
a 2 Mb region, 15q13.3, which can present copy
number variation of zero, one, two, three, or four
copies [19, 20]. This 15q13.3 region contains at
least seven genes [21–23], with at least five distinct
human-specific structural configurations, including a
common inversion [24] (Fig. 1 and Supplementary
Figure 1). The genes include ARHGAP11B, FAN1,
MTMR10, TRPM1, miR211, KLF13, OTUD7A, and
CHRNA7 (Fig. 1). Microdeletions of 15q13.3 can be
homozygous, heterozygous or compound heterozy-
gous. Homozygous and compound heterozygous
15q13.3 microdeletions are associated with severe
phenotypes, which may include intellectual disabil-
ity, dysmorphic features, epilepsy, neuropsychiatric
disturbances with or without cognitive impairment,
schizophrenia and autism [21, 25]. In contrast, indi-
viduals with heterozygous 15q13.3 microdeletions
may show a mild phenotype or complete absence of
anomalies [21–23]. Duplications of 15q13.3 are less
commonly observed than deletions, and less often
associated with intellectual disability [19, 20]. CNVs
of the 15q13.3 region could increase or decrease the
levels of the FAN1, MTMR10, and TRPM1 gene prod-
ucts, which may affect phenotypes. However, the
mechanism by which CNVs of any of these genes
relate to clinical presentations remains unclear. Of the
various genomic configurations of the 15q13.3 region
(Supplementary Figure 1), it is not known which
occur with the HD-modifying FAN1 and MTMR10
variants. It would be interesting to learn whether some
15q13.3 structural configurations are associated with
modifying the presentation of HD, SCAs, autism, or
schizophrenia.
2. FAN1 PROTEIN STRUCTURE, DOMAINS,
AND PROTEIN INTERACTIONS
In 2010, four groups independently identified
KIAA1018 as a structure-specific nuclease required
for DNA interstrand crosslink (ICL) repair; they col-
lectively renamed the protein FAN1 (for FANCD2-
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Fig. 2. Protein domains of FAN1. (a) FAN1 is composed of an unstructured N-terminal region containing the Ubiquitin Binding Zinc (UBZ)
finger domain, a central region containing a SAP domain to mediate DNA binding and a TPR domain required for protein-protein interactions,
and a C-terminal region embedding a VRR NUC domain that harbors the catalytic site. A non-canonical PCNA-interacting peptide (PIP)
motif and a KEN-box motif, which are required for interaction with PCNA and Cdh1, respectively, are located at the N-terminal region. Key
residues of each domain are highlighted in red. Mutations associated with pancreatic cancer and early onset of HD are highlighted with red
and black circles, respectively. (b) Crystal structure of FAN1 revealed that two FAN1 molecules can dimerize to form a head-to-tail dimer
in the presence of DNA. Assembly of FAN1 dimer occurs via the TPR and NUC domains of the first FAN1 molecule interacting with the
SAP domain of a second FAN1 [41]. (c) FAN1 can form different subcomplexes with MLH1, ubiquitylated FANCD2, ubiquitylated PCNA,
or can exist as homodimer in solution.
FANCI-associated nuclease 1) due to its physical
association with FANCD2—a central component of
the Fanconi Anemia (FA) pathway [5–8]. The fun-
damental importance of FAN1 in cell physiology
is underscored by its domain organization, which
is highly conserved among eukaryotes and also
present in some bacteria [5–8] (Fig. 2a, b). All FAN1
orthologs contain a C-terminal PDXn(D/E)XK motif
located within an atypical virus-type replication-
repair nuclease (VRR NUC) domain [26, 27]. FAN1
is the only known eukaryotic nuclease with a
VRR NUC module, which is otherwise common
in bacteriophages and bacteria as a stand-alone
domain. FAN1 preferentially incises 5’-flap branched
structures [5–7, 28] (Fig. 3). However, FAN1’s
substrate specificity appears to be broad; its endonu-
clease activity can efficiently cleave different DNA
intermediates and probably deal with several types
of DNA lesions. Besides its ability to cleave DNA
substrates containing a 5’-flap, FAN1 displays a 5’-3’
exo-nuclease activity that requires gapped, nicked, or
recessed DNA as an entry point [5–7] (Fig. 3) and can
cleave every 3rd nucleotide in small flap non-repeat
DNA [29]. FAN1 can also cleave D-loop structures
that form during homologous recombination repair
(HRR) [6] (Fig. 3). DNA damage induced by exoge-
nous or endogenous chemicals, including ICLs and
oxidative DNA lesions, have also been considered as
targets of FAN1 (detailed in Section 4).
FAN1’s N-terminal region is largely unstructured,
except for a RAD18-like ubiquitin-binding zinc
finger (UBZ) domain, which is required for FAN1
localization to ICLs and stalled replication forks,
possibly through binding to ubiquitylated FANCD2
[5–8, 30]. Consistently, a FAN1 zinc-finger mutant
(C44A/C47A, Fig. 2a) fails to co-localize with
FANCD2 in DNA damage-induced nuclear foci
[5–8]. However, the UBZ mutant is competent in
rescuing from mitomycin C (MMC) sensitivity of
FAN1 knockout cells, suggesting that ubiquitin
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Fig. 3. FAN1 can process various unusual DNA structures, includ-
ing interstrand cross-linked DNA (ICL), dsDNA (supercoiled,
covalently closed circular, linear DNA), nicked DNA, flap-DNA,
R-loop DNA, and repeat containing DNA (unknown). Purple and
red arrows denote exo-nuclease and endo-nucleolytic cleavage,
respectively.
recognition is not essential for ICL repair [30–33].
In agreement with this, the FAN1 p.M50R cancer-
associated mutant—located in the UBZ domain
(Fig. 2a)—equally abolishes FAN1 foci but restores
MMC resistance in FAN1-deficient cells [30],
indicating that other FAN1 domains can mediate
recruitment to ICLs. Indeed, FAN1 harbours a
non-canonical proliferating cell nuclear antigen
(PCNA)-interacting peptide (PIP) box motif that
precedes and acts in concert with the UBZ domain
in binding to ubiquitylated PCNA (ub-PCNA) [34]
(Fig. 2a). A systematic and comparative analysis
measuring the recruitment kinetics of DNA repair
proteins at complex DNA lesions indicated two
separate modes of FAN1 recruitment: an early step
clustering with PCNA and a later step overlapping
with FANCD2 [35]. Moreover, the PIP- and UBZ-
dependent interaction of FAN1 with ubiquitylated
PCNA is reminiscent of that for DNA polymerase η,
acting in translesion DNA synthesis (TLS) [36–38],
and for Spartan, a metallo-protease acting in DNA-
protein crosslink repair [39]. Remarkably, both the
PIP box and the UBZ are well conserved in FAN1
of multicellular eukaryotes including C. elegans,
but absent in S. pombe, suggesting an evolutionary
expansion of FAN1 interaction networks.
FAN1 contains highly conserved SAP (SAF-
A/B, Acinus and PIAS) and TPR (tetratricopeptide
repeat) domains implicated in DNA binding and
FAN1 dimerization [28, 40] (Fig. 2a, b). FAN1 is
monomeric in solution, but dimerizes in the presence
of DNA [28]. Human FAN1 forms an asymmetri-
cal ‘head-to-tail’ FAN1 dimer on DNA (Fig. 2b)
[41]. Dimerization relies on a region of the SAP
domain of one FAN1 molecule interacting with the
TPR and NUC domains of a second FAN1 molecule
[41]. The first SAP domain defines the DNA substrate
orientation, whereas the TPR and NUC domains of
the second FAN1 facilitate the nucleolytic reaction
by engaging the cognate DNA in the catalytic site
[41] (Fig. 2b). While FAN1 dimerization endows
the protein with its specific endo-nuclease activity,
dimerization is not absolutely required for its exo-
nucleolytic function [41]. The FAN1 dimer-DNA
crystal structure displays three different DNA binding
modes (’substrate-scanning’, ‘substrate-latching’,
and ‘substrate-unwinding’), which determine distinct
mechanisms for DNA cleavage [41]. Along this line,
FAN1 homodimers process long (40 bp) but not
short flap (1-5 bp) DNA substrates [42]. Besides
their role in tethering and orienting the DNA sub-
strate for subsequent cleavage, these homodimers
possibly evolved to bind DNA in a conformation
that simultaneously allows interactions with PCNA,
FANCD2-FANCI and other proteins (Fig. 2c). It
would be interesting to elucidate the contribution
of the endo- rather than the exo-nuclease activity
in the processing of damaged DNA, by employ-
ing dimer-defective FAN1 variants (K525E/R526E/
K528E triple mutant or a 510-518 deletion) [41, 42].
Curiously, FAN1 dimerization is unique to higher
eukaryotes [28, 41].
FAN1 was initially detected in a proteomic analysis
of MLH1- and PMS2-interacting proteins, under-
taken to gain novel insights into the function of
MMR [4]. Individual interactions between FAN1 and
MutL homologs were subsequently validated using
reciprocal immunoprecipitations and size-exclusion
chromatography [5, 7]. It is currently unknown
whether complex formation between FAN1 and
MutL, MutL, or MutL heterodimers is mediated
via their common MLH1 subunit or via a common
interaction motif in PMS2, PMS1 and MLH3. MutL-
binding region(s) in FAN1 have not yet been mapped.
MLH1 is not required for nuclease activities of FAN1
in vitro [6]. The FAN1-MLH1 interaction may play
a structural role, which potentially determines DNA
cleavage specificity. Finally, it has been proposed
that FAN1 interacts with MSH2 following treatment
with alkylating agents [43], but this finding has not
been independently confirmed and direct interaction
of FAN1 with MSH2 (or its partners MSH3 or MSH6)
was not demonstrated.
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3. FAN1 AND DNA REPAIR-RELATED
PROCESSES
Loss of FAN1 results in sensitivity to drugs
that induce DNA crosslinks (e.g., MMC, chlo-
rambucil, and platinum-based drugs) [5–8, 44],
albeit far less (by at least 30-fold) than with defi-
ciencies of either FANCA, FANCJ, or FANCQ
(XPF/ERCC4) [6, 45, 46]. Moreover, FAN1 deple-
tion leads to only a very mild (<5-fold) increase
in spontaneous and MMC-induced chromoso-
mal aberrations (chromatid breaks, exchanges, chro-
mosome-type aberrations, multi-radials), compared
to those in FA cells (up to 100-fold) [6, 45]. ICLs can
be processed either in S-phase by replication-coupled
pathways that require the NEIL glycosylase [47] or
FA proteins [48, 49], or in a replication-independent
manner involving TLS or MMR pathways [50,
51]. Both replication-dependent and replication-
independent ICL repair pathways share several enzy-
matic steps, which rely on the activity of structure-
specific nucleases.
FAN1 can cleave ICL-stalled replication-like
structures [29, 52] (Figs. 3 and 4a), indicating its
role in S-phase-dependent ICL repair. There has
been considerable effort to define the function of
FAN1 in processing of DNA modified from endoge-
nous or exogenous sources, but its precise role
in ICL repair is still unclear. ICLs induced by
exogenous compounds—such as cyclophosphamide,
cisplatin, melphalan, psoralens, diepoxybutane, or
MMC—have been used as proxies for the repair of
endogenous ICLs caused by common metabolites,
such as formaldehyde and acetaldehyde (including
that derived from ingested alcohol), and oxidized
lipid species [7, 53, 54]. FAN1 can resolve a subset
of ICL-containing structures, including those where
the replication forks remain some distance from the
damage [52] (Figs. 3 and 4a), thereby generating a
suitable substrate for subsequent nicking by a 3’ flap
endo-nuclease (such as XPF-ERCC1) and DNA syn-
thesis by TLS polymerases (Fig. 4b). Biochemical
evidence suggests that the primary function of FAN1
in ICL repair lies in its ability to ‘unhook’ the DNA
lesion [55]. Although FAN1’s nuclease activity is
well suited for ICL incision in vitro [29], its depletion
in Xenopus egg extracts does not lead to any incision
defects [56]. This discrepancy might reflect a differ-
ence in the chemical nature of the lesions studied. In
the replication-dependent ICL repair system of Xeno-
pus, unhooking only occurs when replication forks
are in very close proximity (at least 5 nucleotides)
to the crosslink: an unfavorable scenario for FAN1
[52, 56]. Alternatively, immune depletion of FAN1
in Xenopus egg extracts may not cause discernable
defects in ICL incision because of redundancy with
other structure-specific nucleases (for review, see
[57]). Thus, in mice, Fan1 is non-epistatic to Slx1
[58]—a nuclease that can process crosslinks by pro-
moting the endo-nucleolytic cleavage of a wide range
of branched structures, including 5’-flaps (Fig. 3).
However, while Slx1 processes ICL-containing struc-
tures at the DNA branch point [59], FAN1 can incise
both the single-stranded DNA (ssDNA) flap, and
double-stranded DNA (dsDNA) region downstream
[7, 28, 41]. FAN1 and SLX1 may cleave distinct ICL-
containing DNA sequences, or they may operate at
different steps of ICL repair, with SLX1 playing a
more prominent role in the unhooking step. FAN1-
mediated cleavage of ICL-containing substrates in
vitro is reminiscent of the activity of SNM1A, the
human homolog of Pso2, a structure-specific nucle-
ase involved in ICL repair in S. pombe [60]. To date,
SNM1A and FAN1 are the only established nucleases
that can traverse crosslinks and exhibit both 5’-flap
endo-nuclease and 5’-3’ exo-nuclease activities [53,
61]. Human SNM1A complements the ICL sensitiv-
ity in yeast that lack Pso2 [60], but its deficiency
confers very mild crosslink sensitivity in mammalian
cells [32], probably because of the redundancy with
FAN1. Accordingly, yeast Fan1 and Pso2 are non-
epistatic in terms of cisplatin sensitivity [40] and
Snm1a partially compensates Fan1 loss in mouse
cells [32].
In addition to a direct role in ICL unhooking, it
has been speculated that FAN1 may act on HRR
intermediates [6, 7] that form during the last step
of the ICL repair process (for review, see [62]).
HRR requires the formation of a DNA double-strand
break (DSB), followed by DNA end resection by
the MRN-RPA-BLM-DNA2-EXO1 machinery [63].
Then, the BRCA1-PALB2-BRCA2 complex [64]
allows assembly of the RAD51 nucleofilament in
order to promote a homology search in the intact sis-
ter chromatid. While FAN1 seems not to be required
for DSB resection [7], its deficiency leads to a delay in
the disappearance of RAD51 foci [6, 7], indicating a
role in the late stage of HRR. Alternatively, ICLs can
result in fork collapse, generating one-ended DSBs
that require break-induced replication (BIR) (a sub-
pathway of HRR) for fork restart (for review, see
[62]). Thus, the lagging strand 5’ to the ICL pro-
vides a potential substrate for FAN1 endo-nuclease
activity, which can create a nick and further promote
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Fig. 4. FAN1 at the cross-road of genome maintenance pathways. (a) FAN1 promotes FA pathway-independent repair of ICLs. FAN1
catalyzes ICL unhooking by endo-nucleolytic incision followed by exo-nucleolytic digestion of DNA past the lesion, thereby generating
a substrate for TLS polymerases (ICLs are indicated by red box). (b) FAN1 interacts with MutL and may function as a compensatory
nuclease in MMR in the absence of EXO1. (c) FAN1 promotes PCNA mono-ubiquitylation on the K164 residue. Further modification of
the same residue via K63-linked polyubiquitination is then required for the recruitment of the ZRANB3 translocase and fork reversal, an
error-free damage tolerance pathway. (d) FAN1 binds ubiquitylated PCNA on K164 and activates a feed forward loop that enhances PCNA
ubiquitylation and possibly TLS (aberrant DNA lesions are indicated by open triangles).
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the trimming of the nascent DNA. This generates a
3’ ssDNA overhang, required for resumption of DNA
synthesis [41, 52]. While FAN1 can cleave ICLs in
vitro, its role in the cellular response to MMC or other
crosslinking agents remains unknown. Therefore, it
is of fundamental importance to functionally delin-
eate FAN1-mediated ICL processing in cells and in
vivo.
FAN1-mediated processing of damaged DNA
relies on its accurate recruitment to the site of the
lesion. Although FAN1 structure might be crucial for
its substrate preference, scaffold proteins are required
to secure its timely localization. Initially, FAN1 has
been associated with the FA pathway because of
its binding to ub-FANCD2—a central component of
the FA machinery. The FAN1-FANCD2 interaction
mediates FAN1 recruitment to sites of ICLs and has
been thought to be crucial for ICL repair. This long-
held belief is now challenged by the evidence that
cells expressing the UBZ-mutated form of FAN1 are
not hypersensitive to MMC [30, 32]. Thus, the con-
tribution of the UBZ domain in FAN1 to ICL repair,
if any, remains largely unknown. It may bypass the
requirement of the FA proteins and become crucial
for ICL repair in a context where the FA pathway is
inactive. Along this line, FAN1 deficiency enhances
ICL-induced genomic instability in FANCD2 null
cells and further sensitizes FANCA-deleted cells to
MMC [32]. Chicken DT40 cells depleted of both
FAN1 and FANCC are more sensitive than wild-
type and single-knockout cells to cisplatin [44]. In
addition, kinetics of FAN1 foci formation is largely
unaffected in PD20 cells that lack FANCD2 [32].
Together, these findings suggest a role for FAN1 in
ICL repair that is outside of the FA pathway, explain-
ing why FAN1 mutations have not been identified
in unclassified FA patients. The chemical nature of
ICLs, the resulting DNA distortion, and the location
of the damage will influence the mode of its repair.
Thus, a role for FAN1 might be in the formation of
a one-ended DSB, only for the subset of forks that
do not physically encounter the cross-link and do
not activate the FA core complex. Intriguingly, FAN1
appears earlier than the FA pathway on the evolution-
ary scale. A FAN1 homolog lacking a UBZ domain is
indeed implicated in the repair of ICLs in unicellular
eukaryotes, such as fission yeast (S. pombe), that do
not possess the FA machinery [40]. We thus speculate
that the FAN1-FANCD2 interaction is not directly
related to the repair of DNA crosslinks, and that an
as-yet unidentified factor is responsible for mobi-
lizing FAN1 to sites of ICL in a UBZ-independent
manner. Localization of FAN1 at sites of ICL dam-
age is biphasic, with an initial rapid recruitment of
the protein followed by a slower but steady accu-
mulation, which coincides with FANCD2 binding
[32]. While the retention of FAN1 at ICLs depends
on its UBZ domain and is not associated with ICL
sensitivity, the first, very fast phase of this process
apparently confers resistance to ICL-inducing drugs
and relies on the FAN1 SAP domain [32]. However,
it is very unlikely that the direct interaction of FAN1
with DNA can specifically drive the protein to ICL
sites in a timely manner. Since the SAP domain is
also involved in FAN1 dimerization, mutations in this
module can perhaps perturb FAN1 dimer structure
and rewire interaction networks, ultimately affecting
FAN1 recruitment.
A direct role for FAN1 in post-replicative MMR
seems apparent, based on its interaction with MutL
homologs MLH1 and PMS2, together forming the
MutL heterodimer [4] (Fig. 2c). The MMR system
detects and removes non-Watson-Crick base pairs in
both mitotic and non-mitotic cells. The absence of
MMR in states of high proliferation leads to high
levels of mutations [65]. Thus, functional MMR is
essential to ensure the fidelity of DNA replication
but also for genome integrity in non-mitotic cells.
Cells treated with the alkylating agent, N-methyl N-
nitrosourea (MNU), accumulate FAN1 nuclear foci
in an MLH1-dependent manner [43]. Authors of
this study propose that FAN1 exo-nuclease gener-
ates ssDNA to activate a DNA damage response,
ultimately triggering apoptosis [43]. To formally
prove a role of FAN1 in MMR, one should mon-
itor the rate of G:C-to-A:T transversion mutations
in a FAN1-deficient background following MNU
treatment. Independent studies reported that FAN1
inactivation causes no evident defect in MMR [5, 66]
in normal settings, but that FAN1 may be one of sev-
eral redundant MMR nucleases, which may include
(but may not be limited to) EXO1, MRE11, Artemis,
FEN1, and XPF [66]. Thus, FAN1-deficiency may
contribute to a partial MMR defect only in certain
genetic backgrounds.
MMR complexes are implicated in recognition
and processing of ICLs and other forms of chem-
ically damaged DNA, in addition to mismatched
bases. In particular, MutS (MSH2-MSH6) binds
to ICL-containing plasmids and promotes recruit-
ment of MutL [51], whereas MutS—which has
higher specificity for larger insertion-deletion loops
(IDLs)—associates with psoralen-induced ICLs
[67]. Recent reports suggest a role for the MMR
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machinery upstream of the FA pathway in the mono-
ubiquitination and chromatin localization of
FANCD2 [68]. Thus, it is conceivable that the FAN1-
MLH1 complex might be recruited to sites of ICLs
in S-phase at an early step that precedes FANCD2
localization. Future experiments should address
whether FAN1-MLH1 interaction is required for the
FAN1-dependent ICL repair, analogously to what
has been proposed for the DNA helicase FANCJ
[69, 70]. In this respect, it will be crucial to test
whether MutL can act as a bridge allowing FAN1
nuclease to pair with the FANCJ helicase during ICL
processing.
4. FAN1 AND DNA REPLICATION STRESS
Replication stress is defined as perturbations in
replication dynamics that alter fork progression. A
number of DNA regions in the genome are intrin-
sically difficult to replicate and might represent a
hurdle for the DNA replication machinery. For exam-
ple, repetitive DNA sequences—such as ribosomal
DNA, telomeres, GC-rich regions and expanded
trinucleotide repeats—can assemble into secondary
DNA structures that are thought to impede fork pro-
gression or cause replication slippage. Other DNA
regions with low density of replication origins, such
as common fragile sites, are prone to form gaps and
stretches of ssDNA; thus, they are tied to replication
stress. Heavily transcribed regions display elevated
levels of stress because of increased probability of a
clash between replication and transcription machiner-
ies. In addition to these endogenous sources, cells
may experience various forms of exogenous DNA
damage that perturb replication fork progression.
Beyond its role in ICL repair, FAN1 contributes to
DNA replication and is associated with replication
stress responses (Fig. 4c, d). The first evidence link-
ing FAN1 to replication fork processing implicates
its nuclease activity in the restart of forks stalled by
aphidicolin (APH), a specific inhibitor of B-family
DNA polymerases [71]. At sites of APH-stalled repli-
cation forks, FAN1 associates with FANCD2 and
the BLM helicase in a trimeric complex to promote
fork recovery and suppresses new origin firing. In
this context, the UBZ domain of FAN1 appears to
be dispensable, whereas its chromatin localization
requires non-ubiquitylated FANCD2 [71]. Upon fork
stalling, FANCD2 targets the replisome by establish-
ing a transient interaction with the replicative MCM
helicase, independently of its mono-ubiquitylation
by the FA core complex [72]. Non-ubiquitylated
FANCD2 may grant FAN1 access to the replication
machinery and permit fork restart in a timely man-
ner. In the absence of FANCD2, FAN1 can be still
mobilized to stalled forks and drive extensive nucle-
olytic processing of nascent DNA strands [71]. Thus,
the major role of the FAN1-BLM-FANCD2 trimeric
complex may be to restrain FAN1 nuclease activity
and ensure appropriate processing of stalled forks.
In particular, FANCD2 might limit FAN1 activity at
stalled forks by stabilizing RAD51-DNA filaments
[73]. The role ascribed to FAN1 in fork metabolism
is reminiscent of that attributed to DNA2—another
nuclease involved in fork restart [74], which can
mediate over-resection of nascent DNA strands if
not kept in check [74, 75]. FAN1 localization at
APH-stalled forks also relies on MRE11’s 3’-5’ exo-
nuclease activity [71], which can reshape the fork
into a suitable substrate for FAN1. Besides its role
in fork restart, FAN1 nuclease activity is required to
restrain replisome progression and preserve genomic
integrity, under conditions of dNTP shortage due to
hydroxyurea treatment [30]. Surprisingly, the UBZ
domain, which is dispensable for FAN1-mediated
fork restart, appears to be crucial for limiting fork
progression and chromosomal instability following
replication stress [30]. Likewise, the FAN1 interac-
tion with ubiquitylated-PCNA is required to limit the
rate of DNA synthesis under replicative stress condi-
tions [34]. Further investigation is needed to establish
how FAN1 can, at the same time, limit fork progres-
sion and promote fork restart. Like FAN1, the HLTF
translocase [76] or the RAD51 recombinase [77]
can restrain DNA synthesis during replication stress
by promoting fork remodeling—a process that con-
verts replication forks into four-way structures and
back. Replication fork reversal allows the replisome
to bypass UV-damaged templates [78] and represents
a pathway that allows DNA replication to pause and
resume once the damage is repaired (for review, see
[54]). Thus, it is tempting to speculate that FAN1-
dependent processing of stalled forks might operate at
the initial step of fork reversal by promoting localiza-
tion of the SNF2 family DNA translocases—such as
ZRANB3, HLTF and/or SMARCAL1—whose activ-
ity has been involved in fork regression [79]. In
particular, ZRANB3 fulfills its functions by binding
poly-ubiquitylated PCNA. In response to replication
stress, FAN1 activates a feed-forward loop able to
enhance levels of mono-ubiquitylated PCNA, pro-
viding potential substrates for poly-ubiquitin chain
extension. The latter will ultimately help ZRANB3 to
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engage replication factories efficiently and promote
regression of the stalled fork. Future research should
aim to prove this model and determine whether FAN1
accomplishes its replicative function by promoting
fork reversal (Fig. 4c). On the other hand, given that
the formation of reversed forks places the DNA lesion
back into the context of dsDNA, we cannot rule out
a role for FAN1 in the incision of the region flanking
the damage, analogous to its putative function in ICL
repair.
Alternatively, FAN1 can channel stalled forks
into the TLS pathway, allowing replication through
a damaged template with low processivity and
fidelity (Fig. 4d). FAN1 might indeed process forked
DNA in a way that generates RPA-coated ssDNA:
a pre-requisite for the recruitment of the E3 ligase,
RAD18, and subsequent PCNA ubiquitylation [80].
Ubiquitylated -PCNA can enable mobilization of
TLS DNA polymerases, which bypass bulky lesions
in a post-replicative manner (Fig. 4d). The latter may
account for the limited fork speed observed in FAN1-
proficient cells upon replication stress induction.
On the other hand, permissive replication detected
in FAN1-deficient cells might be associated with
extensive repriming and/or unscheduled origin firing.
Both of these processes lead to an excess of ssDNA
gaps that, if left unreplicated, might overwhelm the
post-replicative repair mechanisms in G2, generat-
ing DSBs and chromosomal instability. Thus, a key
objective for future research will be to investigate
whether unrestrained replication in FAN1-deficient
cells generates S1-nuclease-sensitive tracts, which
would indicate ssDNA regions. Moreover, it will be
important to explore the role of FAN1 in replisome
surveillance in cells lacking either PrimPol—which
has emerged as a key factor in re-priming [81]—or
Cdc7 kinase activity, which otherwise stimulates dor-
mant origin firing [82]. Such studies will help to
define whether FAN1 may serve as a molecular
switch to balance fork reversal, TLS, or re-priming
events during replication stress.
5. FAN1 DEFICIENCIES AND VARIANTS
IN GENETIC DISEASES AND CANCER
Many FAN1 variants have been associated with
various diseases, including CAG/polyQ-diseases,
karyomegalic interstitial nephritis (KIN), cancer,
autism spectrum disorder, schizophrenia, epilepsy
and Rett syndrome [14, 25, 31, 83–86] (Fig. 5). The
relative contribution of FAN1 variants to each of the
associated phenotypes is unknown. The connection
of FAN1 to KIN is by far the strongest, possibly fol-
lowed by the modifier association with HD. Although
ranking the strength of the other disease associations
with FAN1 is difficult, we have approximated them
by the size of the arrows in Fig. 5. The weight of
the data supporting these associations varies, as dis-
cussed below. These variants and associated clinical
presentations are summarized in Table S1, with vari-
ants pertinent to this review highlighted in Fig. 1b
and d. The mechanism by which any of these vari-
ants contribute to the various clinical presentations is
unclear but discussed in the sections that follow.
5.1. Karyomegalic interstitial nephritis
(KIN; OMIM#614817)
Bona fide autosomal recessive mutations in FAN1
lead to KIN (Fig. 5), a rare hereditary genetic dis-
order that leads to chronic interstitial nephropathy,
first described more than four decades ago [87–89].
To date, more than 50 cases have been reported
(reviewed by Isnard et al. [90]). KIN usually presents
as a slowly progressing chronic kidney disease
leading to end stage renal dysfunction in early adult-
hood [91]. The analysis of renal biopsy specimens
usually shows non-specific but severe chronic inter-
stitial fibrosis and tubular changes, associated with
non-specific glomerulosclerosis and vascular lesions.
Genetic deficiencies of FAN1 have been identified in
individuals affected by KIN [31]. Parenchymatous
organs, such as liver, and kidney, neuronal tissue,
and reproductive tissues show high levels of FAN1
expression [31], thus explaining why FAN1 variants
might cause KIN (Supplementary Table 1). The dis-
order is characterized by fibrosis of renal tubules;
it differs from other forms of chronic kidney dis-
ease by virtue of the pronounced enlarged polyploid
nuclei in the renal epithelium, rarely observed in other
organs [92–95]. The source of the organ specificity
of KIN is obscure. Kidney cells from KIN individ-
uals showed > 84% spontaneous hyperploidy; most
were hyper-tetraploid 8-16C, but some had as many
as 81 genomic equivalents [91, 96]. Consistently,
Fan1-deficient mouse models recapitulate hallmarks
of KIN pathology and also display liver function
abnormalities, with hepatocytes showing increased
ploidy [32, 58, 97]. Zhou et al. studied ten families
with KIN [31] and identified 12 different muta-
tions of FAN1 in 9 of the families (Supplementary
Table 1). Eight of the 12 mutations truncate the nucle-
ase domain and three missense mutations (p.Q929P,
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Fig. 5. Overview of FAN1 genetics and its associated diseases. (a) Heterozygous microdeletion in the FAN1 gene is associated with a mild
form of 15q13.3 microdeletion syndrome. Whereas homozygous microdeletion or compound heterozygous microdeletion is associated with
increased severity. Microduplications can be associated with various symptoms. (b) Defects in FAN1 identified in various diseases (c). These
defects may be due to alternative splicing. It may generate aberrant transcript, which further on translation produces either functional protein,
coding variants, or truncated FAN1 protein. (d) Various forms of FAN1 proteins are identified in multiple diseases such as truncated protein
and coding variants are identified in various cancers, KIN, schizophrenia, autism, and some disease hastening coding variants identified in
HD and SCAs. The relative strength of these associations varies widely and are discussed in the text. Arrows that are bold, medium and
dotted denotes strong, moderate and limited evidence for the disease association, respectively. The mechanism associated FAN1 role with
all of these diseases is unknown.
p.G937D and p.D960N) are in evolutionarily con-
served amino acid residues of the FAN1 nuclease
domain [31]. They found none of these mutations in
96 healthy individuals. Consistently, mice express-
ing a truncated form of Fan1, devoid of its nuclease
activity, develop a mild form of KIN [58]. Anal-
ysis of medical records showed that the p.R507H
variant of FAN1 associated with KIN in population
cohorts, contributing in unknown ways [98]. It is
notable that multiple individuals with homozygous
15q13.3 microdeletions encompassing FAN1 do not
show signs of KIN; rather they present with global
developmental delay or intellectual disability, and
severe hypotonia [23, 45, 99–106]. A major open
question in the pathophysiology of KIN concerns the
nature of the lesions repaired by FAN1. Polyploidy
(up to 8C) observed in Fan1-deficient mice increases
during development or in response to ICL-inducing
agents, but not to hydroxyurea [32, 58], suggesting
that increased ploidy arises by a defect in ICL repair
or in the processing of ICL-stalled replication forks.
The increased ploidy might be a direct consequence
of re-duplication of the whole genome or might reflect
the presence of portions of the genome that are under-
replicated. Either way, the appearance of polyploidy
implicates replication cycles not followed by accurate
mitosis. The ICL-induced polyploidy is independent
of FANCD2 [58].
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5.2. Cancer
FAN1 deficiency or variants are associated with
cancer (Supplementary Table 2), however, FAN1 is
not a FA gene per se. Individuals carrying FAN1-
deficiencies do not present with the clinical attributes
typical of FA patients (i.e., anemia, bone marrow
failure, skin pigmentation anomalies, skeletal abnor-
malities of the upper limbs, or spontaneous leukemia)
[45]. Aged mice carrying a defective Fan1 nuclease
domain do eventually develop pulmonary carcino-
mas and hepatic lymphomas [30]. Fan1-deficient
mice do not display discernable defects in bone
marrow histology nor attrition of the hematopoi-
etic stem cell compartment [30]. The p.M50R of
FAN1 increases risk of colorectal cancer (CRC)
[107] and occurs as germline mutation in human
hereditary pancreatic cancers [33]. Heterozygous
germline FAN1 mutations in MMR-proficient fam-
ilies suggest that it may be a CRC susceptibility gene
[108]. A meta-analysis suggested that the contribu-
tion of FAN1 to CRC is doubtful, as the evidence
of segregation is weak (p = 0.125), with no somatic
mutations of FAN1 in tumors from any of the FAN1
mutation carriers [108, 109]. Consistent with this,
another meta-analysis raises serious concerns about
the role of FAN1 in cancer progression and predispo-
sition [85]. Among > 5000 cancer patients clinically
suspected as having genetic predisposition to colorec-
tal, ovarian, breast, and other cancers, monoallelic
pathogenic FAN1 variants were identified in 0.35%.
However, the expected frequency of heterozygous
mutations in patients and the general population is
also not significantly different [85]. No CRC was
reported in the first- or second-degree relatives of any
of the 16 index cases with pathogenic FAN1 variants.
No cancer was identified in close blood relatives of
four index cases with KIN carrying biallelic germline
mutations of FAN1 nor in patients with homozygous
15q13.3 microdeletions encompassing FAN1 [85,
104]. Larger CRC series could provide more infor-
mation about the prevalence of FAN1 pathogenic
variants. A thorough analysis of genetic and genomic
alterations found in FAN1-associated tumors will be
important to clarify the underlying repair defects
accumulated by these cells and mechanism of action
of FAN1 in colorectal carcinogenesis. Interestingly,
FAN1 may acquire a key role in cancer cells lack-
ing BRCA2 [34]. BRCA2 is an important factor of
HRR and acts as reservoir of the RAD51 recombinase
[64, 110–113]. Deposition of RAD51 by BRCA2
not only facilitates HRR but has a fork-protective
function by preventing replication stress in a man-
ner distinct from HRR [114]. FAN1 limits replication
stress and genome instability in BRCA2-deficient
cells [34] and may provide a protective mechanism
in cancer cells lacking BRCA2, ultimately affecting
cell survival and treatment responses. In light of these
data and resolution of the FAN1 crystal structure,
FAN1 inhibitors could be developed for treatment of
BRCA2-deficient tumors. Finally, increased FAN1
expression correlates with poor prognosis of breast
and ovarian cancers that are refractory to therapy
[115]. Therefore, FAN1 might be a novel promis-
ing target for cancer therapy or be used as potential
biomarker to predict the insurgence of drug resistance
in breast and ovarian cancer.
5.3. Neurodevelopmental and neuropsychiatric
diseases
FAN1 copy number variations (CNVs), via dele-
tions and duplications of the 15q13.3 region, are
associated with autism, schizophrenia, and epilepsy
[21, 25, 83, 84] (Fig. 5). These neurodevelopmental,
psychiatric, and neurological disorders, respectively,
share genetic predisposition factors [21, 25, 83, 116,
117]. Whole exome sequencing of autism patients
and whole genome sequencing of schizophrenia
patients identified various variants including FAN1
missense variants associated with both autism and
schizophrenia [25, 83, 84] (Supplementary Table 2).
Likewise, recurrent FAN1 CNVs predispose to an
array of psychiatric and neurodevelopmental disor-
ders [116, 117]. A homozygous knock-out mouse
model involving the ortholog to a 1.5 Mb region
of chromosome 15q.13.3 spanning Fan1 and seven
adjacent genes displays strong phenotypes related to
autism, schizophrenia, and epilepsy [21]. However,
the degree to which these phenotypes are related to
CNVs of FAN1, as opposed to any of the adjacent
genes, is unknown.
Soon after the discovery that myotonic dystrophy
and HD are caused by expanded tandem DNA repeat
sequences, it was hypothesized that autism spectrum
disorder (ASD), schizophrenia (SCZ), and epilepsy
might also be caused by repeat expansions [118–120].
Indeed, various forms of epilepsy, SCZ, and—most
recently—ASD are associated with repeat expansions
[121–126]. Strikingly, Yuen and colleagues recently
broadened, by leaps and bounds, the awareness of
both the sequence motifs and the number of repeat
loci that can be associated with a neurological pheno-
type [122]. FMR1 CGG expansions cause a spectrum
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of clinical presentations, including fragile X syn-
drome (FXS), autism, fragile X-associated ataxia,
premature ovarian failure/insufficiency, attention-
deficit disorder, learning disabilities, as well as psy-
chological, endocrine, autoimmune, and metabolic
disorders [127]. Other fragile sites caused by CGG
expansions have also been associated with ASD.
Ionita-Laza et al. reported numerous variants in
FAN1 as modifiers of ASD and SCZ [25], including
p.R377W and p.R507H, which were subsequently
identified as modifiers of onset in HD [14, 15]. The
role of FAN1 in any of these disorders and the
underlying mechanisms by which it might mediate
pathological effects need further investigation.
A coding variant of the murine Fan1 is a modifier
in Rett syndrome mice [86]—a neurodevelopmental
autism-like disorder that occurs primarily in females.
We feel that this finding is worth some attention for
future studies in humans. Rett syndrome is caused
predominantly by mutations in the Methyl-CpG-
binding protein 2 (MECP2) gene; “atypical” Rett syn-
drome can result from variants in FOXG1 or CDKL5
[128–130]. A recent study screened for modifiers
that improve subjective phenotypes in Mecp2/Y mice
after mutagenesis with N-ethyl-N-nitrosourea [86].
Phenotypes assessed included limb clasping, tremors,
body weight, activity, and longevity. Amongst several
pathways, many of the identified modifier variants
were in DNA damage response genes (Birc6/BRUCE,
Brca1, Brca2, Fan1, Mre11a, Rad50, Rbbp8/Ctip,
Tet1, and Spin1) [86] providing the first instance
by which this mechanism may contribute to Rett
syndrome. Absence of MECP2 is associated with
the accumulation of DNA damage [131]. The Rett-
modifier in murine Fan1 corresponds to a S798P
change in human FAN1 (Fig. 1), which is in between
a highly conserved TPR and nuclease domain. How
this Fan1 variant modifies the Mecp2-deficient phe-
notypes, and whether such modifications extend
to humans with Rett syndrome, requires further
investigation.
6. GENETIC MODIFIERS OF CAG/POLYQ
EXPANSION DISEASE ONSET
Certain neurodegenerative diseases are caused by
the expansion of gene-specific CAG repeat sequences
that encode polyglutamine (polyQ) tracts. Such
diseases include HD (OMIM#143100), spinocere-
bellar ataxia type 1 (SCA1 OMIM#164400), SCA2
(OMIM#183090), SCA3 (OMIM#109150), SCA6
(OMIM#183086), SCA7 (OMIM#164500), SCA17
(OMIM#607136), and others. The age of onset of
symptoms correlates with the length of the inherited
CAG tract at the disease locus [132]. For the same
inherited CAG size a broad range of onset age can
occur, but less so within a given family [133], suggest-
ing genetic modifiers of disease onset, independent
of CAG tract size, must exist. Furthermore, Wexler
et al. showed that 40% of the variance in age at onset
in HD not attributable to CAG length, was heritable
and therefore genetic [134].
The most robust evidence of DNA repair gene
variants—including in FAN1—as modifiers of dis-
ease is for HD, where genome-wide analyses
involve the greatest number of patients (HD cohorts
of ∼4000–9000), with strong clinical assessments
(reviewed in [135]). The HD GWAS generated a sta-
tistical phenotype model, based upon HD subjects
with 40–55 CAG repeats in the HTT gene in their
blood DNA, to calculate the influence of the repeat
length on age at onset of motor signs [15]. That
study generated for each subject a “residual age at
motor onset” value, which represents the difference
in years between actual age at onset and that expected
based upon the repeat size. These residual phenotype
values were used to search the individuals genomes
for genetic variations associated with HD age at
onset, identifying tagSNPs that define the modifier
haplotype.
6.1. FAN1 variants in CAG/polyQ expansion
diseases hasten or delay disease onset
DNA repair genes, MLH1, PMS1, PMS2, MSH3,
LIG1, RRM2B, and FAN1 act as modifiers of HD
[14]. The strongest by far is FAN1, with both disease-
hastening and disease-delaying tagSNP haplotypes
[14,15] (Fig. 1b, d). Details about these HD modifier
haplotypes are outlined here. For simplicity, we gen-
erally refer only to specific SNPs (rs#s), rather than
to the haplotypes (please see Fig. 1d, and the review
by Hong et al. [135]). Assessment of other diseases
with CAG/polyQ expansion (SCA1, SCA2, SCA3,
SCA6, SCA7, and SCA17) also identified variants
in FAN1 as the strongest modifiers [136–138]. Those
that act as modifiers of age of onset, the haplotype
size, tagSNPs, genic location, and expected and doc-
umented effects, are summarized in Fig. 1d. Notably,
some FAN1 variants hastened or delayed disease
onset by as much as ∼6 years from that expected
for the inherited CAG expansion size.
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6.2. Modifiers may alter expression levels of
FAN1 mRNA
The tagSNPs of FAN1 associated with modifying
HD onset may be associated with altered expression
of FAN1 mRNA, whereby increased or decreased
FAN1 levels are beneficial or detrimental, respec-
tively [12, 14, 15, 139]. Both expression quantitative
trait loci (eQTL) and transcriptome-wide association
studies [140] suggest that the SNPs are associated
with changes of FAN1 mRNA expression levels in
specific brain regions but have no apparent effect
on the expression of proximal genes, including
MTMR10 or TRPM1 [12, 141]. In some individuals
with HD, the onset-delaying FAN1 modifier over-
rides the effect of the onset-hastening haplotype on
the other FAN1 allele [12]. These data support the
concept that increased expression of FAN1 protein,
and/or its functions, correlates with delayed onset
and slower disease progression. For example, the
tagSNPs rs35811129 and rs34017474 both corre-
spond to cis-eQTLs for increased FAN1 expression in
cortex [12, 14, 141] and are associated with delayed
age of onset. However, the 15AM4 haplotype asso-
ciated with tagSNP rs34017474 does not capture
single modifier effects; rather, a combination of the
effects of the 15AM1, 15AM2, 15AM3 and 15AM5
haplotypes.
Expression studies provide a guide to how spe-
cific genetic variants might affect disease onset and
progression but must be interpreted with caution.
While the effects of FAN1 variants upon its own
mRNA expression in the cerebral cortex appear to
correlate consistently with suspected increased or
decreased levels of FAN1 protein, other factors must
be considered. Notably, these FAN1 expression stud-
ies use database (GTEx, CommonMind Consortium,
and ROSMAP) from tissues of genetically defined
individuals that were not affected with a CAG/polyQ
disease [12, 14, 137, 141]. Individuals with HD have
transcriptome-wide alterations, including in DNA
repair genes, which must be accounted for [142,
143]. These dysregulated transcripts are evident in
cell lines and patient tissues, and in many instances
(but not all) are matched at the protein level [142,
143]. The size of the HTT repeat expansion can
affect the degree of DNA repair gene dysregulation.
For example, isogenic HD human pluripotent stem
cells (hPSCs) with CAG lengths of 30, 45, 65, or
81 repeats, show increased expression of the DNA
repair genes, FAN1, PMS2 and MSH3 at longer CAG
repeat lengths [139]. Levels of the FAN1, PMS2,
and MSH3 proteins are significantly lower in HD
brains compared to age-matched controls [139]. Such
expression level variations may change as disease
progresses. Tissue-specific expression effects can be
important variables. For example, in different tis-
sues, the rs3512 FAN1 variant can have increasing
or decreasing effects upon FAN1 mRNA expression
levels [137]. In FXS mice, expression levels of Fan1
mRNA does not correlate to levels of Fan1-linked
suppression of CGG expansions between the tissues
[144]. Changes in mRNA expression levels do not
always parallel changes in protein levels. None of the
initial FAN1 expression studies assessed FAN1 pro-
tein levels in any tissue [12, 14, 137, 141]. However,
in human brains, FAN1 is decreased in the cortex of
individuals with HD, while no significant difference
is observed in the striatum [139]. Thus, haplotype-
specific transcription level variations from non-HD
databases are potent predictors of mechanism, but
the expression level differences must be validated in
the appropriate patient cells/tissues or experimental
systems. Complexities of FAN1 expression on CAG
instability are discussed further in Section 7.2.
Limited data from HD patients support the con-
cept that altered levels of FAN1 correlate with
disease onset. As noted above, CNVs of the 15q13.3
region could increase or decrease the levels of
FAN1 and adjacent genes, which may affect dis-
ease. Some individuals with HD who carry three
complete copies of FAN1 (due to duplication
of chr15:30900000-31500000) have significantly
delayed onset compared to those with two allelic
copies [12]. This finding supports the concept that
increased FAN1 levels can be protective for HD; how-
ever, one cannot exclude the possible contribution
of increased levels of other genes in the triplicated
region, nor the presence or absence of any associated
variants. It is important to distinguish the possi-
ble contribution of CNVs relative to any identified
disease-modifying single nucleotide variants. This
is particularly important in regions prone to CNVs,
such as 15q13.3, which encompasses FAN1. CNVs
are not responsible for the effects of individual single
modifiers in the region [12].
6.3. FAN1 coding variants, DNA binding, and
nuclease activities
Understanding the mechanism(s) by which the
FAN1 coding variants may alter disease is of great
interest. Current thinking is that FAN1 may modu-
late repeat instability [12, 141]: a concept supported
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by the hyper-instability of the expanded CGG repeat
in somatic tissues of Fan1-deficient FXS mice [144];
however, biochemical evidence supporting this role is
limited. So far there is no direct biochemical evidence
of FAN1’s role in the binding and processing of DNA
repeats. FAN1 can recognize various secondary struc-
tures in vitro, such as chemically crosslinked DNA
and DNA flaps [5–7, 29, 52] (Fig. 3). Two variants of
FAN1 that result in amino acid changes—p.R377W
(rs151322829) and p.R507H (rs150393409)—are
associated with hastening HD age of onset by 3.2
and 5 years, respectively [12, 14] (Fig. 1d). The
p.R377W variant is proximal to Y374, which—along
with Y436—contacts the DNA single-strand-duplex
junction; these are required for appropriate DNA sub-
strate orientation [29] but not DNA binding [41].
The missense mutation, Y374F, when coupled with
Y436F, significantly impairs endo-nuclease activity
on a 5’ flap [41]. The HD onset-hastening p.R507H
variant is located within the SAP-containing domain
implicated in DNA binding [41]. One might spec-
ulate that the FAN1 coding variants might affect
the biochemical activities (DNA binding, protein
dimerization, nuclease activity, etc.) of the FAN1
protein. The p.R377W and p.R507H FAN1 vari-
ants have decreased DNA binding to flapped-DNAs
relative to that of the wild-type (wt) FAN1 [12].
Notably, this study used an indirect streptavidin-
biotin-oligo pull-down method, with a crude nuclear
extract from FAN1 knockout HEK293T cells over-
expressing transfected FAN1 [12]. Binding constants
were not calculated. The reduced DNA binding by
the variants was evident whether the substrate con-
tained a (CAG)10 loop-out or was devoid of repeats
[12]. Binding activity for the FAN1 variants was
assessed for only CAG (not CTG) slip-outs, and
nuclease activity was not assessed. It is notable,
that several nuclease-dead FAN1 mutants have DNA
binding activities that do not reflect their absent
nucleases activities. For example, the nuclease-
dead mutant FAN1p.D960A, retains DNA binding
capacity comparable to FAN1p.wt. In contrast, the
FAN1p.K525E/R526E/K528E shows undetectable DNA
binding, undetectable endo-nuclease activity, but
exo-nuclease activity comparable to wildtype FAN1
[6–8, 41].
FAN1 does not preferentially interact with the
expanded CAG tract of the endogenous mutant HTT
gene, as measured with chromatin immunoprecipi-
tation (ChIP) [141]. No difference in FAN1 binding
could be detected by ChIP between FAN1 wt/wt or
p.R507H/wt HD cells. FAN1 binding assessed by
ChIP at different genes with CAG, CTG, or CGG
repeat tracts at other disease related genes (TBP,
ATXN3, DMPK, or FMR1) is also not enriched at
the expanded HTT CAG repeat nor any of the other
non-expanded repeat genes. It is possible that ChIP is
unable to detect subtle differences in DNA substrate
preference, or between FAN1wt/wt and p.R507H/wt.
Nucleases can be classified as sequence-specific
or structure-specific. DNA nucleases cleave the
phosphodiester bond, yielding one cleavage prod-
uct containing a 5′-terminal phosphate and one
containing a 3′-terminal hydroxyl group. Nucleases
can be further classified as endo-nucleases—which
hydrolyse internal phosphodiester bonds—or exo-
nucleases, which hydrolyse from the 5′ or 3′ ends
of nucleic acids. Some nucleases are either endo- or
exo- or can have both endo- and exo-nucleolytic activ-
ity. FAN1 is a structure-specific DNA nuclease with
both endo- and 5′ → 3′ exo-nuclease activity.
The nuclease activity of FAN1 was reported as
not necessary for FAN1’s effect upon CAG/CTG
instability [141]. To examine FAN1 function in
repeat instability, FAN1 knockout U2OS cells with
a stably integrated (CAG)118 construct, were recon-
stituted with FAN1p.wt, nuclease-dead FAN1p.D960A,
or FAN1p.R507H [141]. Repeat expansion was sig-
nificantly slower in all FAN1 reconstituted lines
compared to that in FAN1 knockout cells. There
was no difference in CAG expansion rates between
cells expressing the FAN1p.wt and those with either
the FAN1p.R507H or the nuclease-dead FAN1p.D960A
mutant. Thus, neither the R507H nor the nuclease
activity had any effect on CAG instability. Expres-
sion of the FAN1p.D960A mutation on a p.R507H
background did not affect CAG expansion rate rela-
tive to that of the catalytically active FAN1p.R507H.
These results led those authors to conclude that
FAN1 “nuclease activity is not required for protec-
tion against CAG repeat expansion . . . FAN1 affects
somatic expansion of the CAG repeat through a
nuclease-independent mechanism.” [141]. This is a
counter-intuitive finding, as all FAN1 biological func-
tions characterized to date depend on its nuclease
activity [29, 32, 52, 97]. The exogenous repeat assay
system and/or the induced overexpression of exoge-
nous reconstituting FAN1 genes may not have been
sensitive enough to “reveal’ a subtle contribution
from the nuclease activity. It is possible that the pro-
ficient DNA binding activity of the nuclease-dead
FAN1p.D960A [41] may, with its over-expression, in
some way suppress CAG instability, as opposed to the
expected enhanced CAG expansion observed in cells
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lacking FAN1. Therefore, FAN1 nuclease activity
could be more directly assessed via targeted mutation
of the endogenous FAN1 nuclease domain in cells or
an animal model.
One HD individual with a heterozygous rare
mutation truncating the FAN1 nuclease domain
(rs184745027; p.R952∗), had disease onset 11.7
years earlier than expected from CAG repeat length
[12]. Biochemical experiments of FAN1 acting on
repeat DNAs, additional cellular, and in vivo model
system data are needed to determine the roles of the
known FAN1 activities in modulating repeats and
disease. It is worth noting that Exo1, like Fan1, sup-
presses CGG expansions, where Exo1 acts mainly in
the gonads and Fan1 affects expansions in somatic
tissues, but less so in the germline. Exo−/− did not
affect CAG instability in brain, liver, kidney, or heart,
but did in intestine. In contrast, Fan1−/− affected both
CGG and CAG instability in each of those organs, but
not in the germline transmitted lengths. Interestingly,
the Exo1p.D173A mutant, which abolishes its nucle-
ase activity but retains its native conformation and
DNA binding activity, shows a partial suppression of
transmitted CGG expansions, intermediate between
Exo1+/+ and Exo1−/− animals [144]. Thus, in the
mouse germline, this supports suppression of CGG
expansions by Exo1 via both nuclease-dependent and
nuclease-independent pathways.
7. FAN1 IN REPEAT INSTABILITY
7.1. Candidate nucleases in repeat instability;
questionable involvement of Flap
endonuclease 1 (FEN1)
There must be a DNA nuclease involved in the pro-
cess of dynamic disease-associated repeat expansions
and contractions; however, it is unclear which one is
key. Candidates that have been tested include both
endo- and exo-nucleases that recognize unusual DNA
structures [145]. These include Rad27/Fen1/FEN1,
DNA2, RecJ, Exo1/EXO1, SbcCD/Rad50/Mre11,
Mus81-Eme1, APE1, GEN1, ERCC1-XPF, XPG,
and WRN, which have been tested for a possible
role in repeat processing or instability; in vitro assays
and models range from bacteria, yeast, fruit flies, and
mice, to human cells [146–193]. Considerable effort
has been invested into FEN1, the Flap endo-nuclease
1 and its possible role in disease-associated repeat
instability. In yeast, deficiencies of Rad27—the yeast
FEN1 homolog—increase CAG repeat expansions
and contractions [149]. Yeast show a CAG contrac-
tion bias, in contrast to the expansion bias in humans.
Transgenic mice and humans reveal no involve-
ment of FEN1 in CAG repeat instability [167, 188,
194]. Moreover, genetic variants of FEN1, known
to be involved in cancer, show no disease associa-
tion in families with either HD or Fuchs endothelial
corneal dystrophy (FECD) (both CAG/CTG expan-
sion diseases) [188, 194]. While it seems intriguing
that FEN1 can act upon flap-DNAs free of repeats,
but its nuclease activity is inhibited by the pres-
ence of CAG/CTG hairpins, the relevance of this to
repeat instability is unclear [160–162]. Until recently,
there had been no human genetic evidence impli-
cating involvement of any particular exo-nuclease.
FAN1 was the first endo-/exo-nuclease implicated in
humans, as FAN1 is the strongest modifier in genome-
wide association studies searching for modifiers of
age of onset for HD [14, 15].
7.2. FAN1 variants modify disease by modifying
repeat expansions
Attempts to decipher the role of FAN1 and its
variants in repeat instability have yielded mixed find-
ings. One mechanism by which the coding FAN1
variants might hasten onset of CAG/polyQ disease
is through enhancing high levels of somatic repeat
expansions. Initially, variants were tested for their
impact on ICL repair/sensitivity. The effects of two
coding FAN1 HD-modifying variants, p.R377W and
p.R507H, upon the function of FAN1 are limited,
and somewhat contradictory. A knockout of FAN1 in
HEK293T cells causes mildly increased sensitivity
to MMC, which is rescued by transient expres-
sion of wt FAN1, but not by either variant form
[12]. In contrast, the wt or the p.R507H FAN1
rescued to comparable levels the increased MMC
sensitivity in FAN1-deficient U2OS cells [141]. Lym-
phoblasts from HD individuals with p.R507H/wt
FAN1 show increased MMC sensitivity, compared
to those with wt FAN1 [12]; however, another report
shows no such difference [141]. The contradictory
results may reflect other genetic variations between
individuals, the numbers of HD lines studied, or
different model cell systems, using different exper-
imental conditions. The link (or lack thereof) of
FAN1’s roles in repeat instability and any of its
many known functions, including ICL processing,
is unknown.
There are other instances of seemingly contradic-
tory findings for the effect of the FAN1 variants. For
example, the non-coding rs3512 FAN1 variant is one
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of the strongest modifiers delaying onset for HD,
SCA1, SCA2, SCA3, SCA6, SCA7, and SCA17 [15,
136–138], and would be predicted to be associated
with decreased somatic CAG expansions. However,
while rs3512 is associated with increased FAN1
expression in blood [137], increased CAG expansion
rates were detected in blood cells of HD individu-
als with this variant [137]. The association of rs3512
with increased somatic CAG expansions is incon-
sistent with the suspected decrease in somatic CAG
expansions by which this variant would mediate a
later age of onset. However, it is possible that this
variant acts upon repeat instability differently in brain
than in blood.
Deciphering the mechanism by which any one
DNA repair gene variant may act on HD age of onset
and/or CAG instability, is likely to be complex. For
example, the FAN1 rs3512 variant was associated
with delayed onset for HD, SCA2, and some, but not
all SCA3 populations [138, 195]. The rs3512 vari-
ant in a cohort of Chinese SCA3 patients was not
significant, a discrepancy attributed to the diverse
allele frequencies between ethnicities [196]. More-
over, the effect of the rs3512 variant in another cohort
of SCA3 affected individuals was modulated by the
size of non-diseased CAG lengths of the ATXN2 CAG
repeat, whose repeat when expanded causes SCA2
[138]. In fact, mounting evidence suggests that the
presence of intermediate non-diseased sized CAG
tract lengths at other disease repeat expansion genes
can significantly modify the age of onset for a repeat
expansion at another disease loci in the same indi-
vidual [138]. The age of onset in HD individuals
with HTT CAG expansions is modulated by CAG
repeat sizes in the normal range of three other repeat
expansion disease loci, ATXN3, (SCA3) CACNA1A
(SCA6) and AR (SBMA) [197]. These associations
suggest an interaction of these genes/gene products,
possibly in a shared pathway. Notably, mutant HTT
protein was recently shown to interact with the ataxin-
3 protein, encoded by ATXN3, in a DNA repair
complex [198, 199]. Asides from the ATXN2-SCA3-
FAN1 rs3512 association, whether these non-disease
CAG tract lengths affect other disease modifiers is
unknown. Also, an onset-delaying FAN1 modifier
can effectively be cancelled by other mutations. For
example, one HD individual homozygous for the
onset-delaying FAN1 modifier rs35811129, expected
to over-express FAN1 also had a rare mutation trun-
cating the nuclease domain (rs184745027; p.R952∗)
in one FAN1 allele [12]. Rather than delayed disease
onset, this individual had onset 11.7 years earlier than
expected by their inherited CAG repeat length. Thus,
the heterozygous loss of FAN1 nuclease activity
produced an onset-hastening effect, over-riding the
effect homozygous onset-delaying modifier. Thus,
modifiers within the same modifier gene, or in sep-
arate modifier genes may synergize or cancel each
other out.
In FAN1-knock-out U2OS cells, CAG expansions
in an HTT (CAG)118 construct were greater than
in cells that had wt FAN1 added [141]. However,
as noted in Section 6.2, that system was unable to
distinguish between the effect of wt FAN1 and that of
p.R507H, or the nuclease-dead, p.D960A, even with
the latter on a p.R507H background [141]. Thus, the
effect of either the HD-hastening variant, R507H, or
the nuclease domain could not be discerned relative
to CAG instability. In iPSCs derived from an HD indi-
vidual with (CAG)120 in the endogenous HTT gene,
the repeat tract expanded by ∼1 CAG unit every 12.4
days, over ∼60 days [141]. ShRNA-mediated knock-
down of FAN1 significantly increased this to ∼1 CAG
unit every 9 days [141]. Similar effects were observed
when the iPSCs were differentiated to post-mitotic
medium spiny neurons: the vulnerable cell type in
HD. Similarly, knocking out FAN1 in HD-derived
iPSC cells with (CAG)72, using CRISPR/Cas9, lead
to gradual increases in the modal repeat size by ∼1-5
units over six months of cell culture [12]. These
results support a role of FAN1 in slowing, but not
arresting, the rate of spontaneous CAG expansions
of the endogenous HTT expanded CAG repeat. Since
FAN1 can affect both CGG and CAG repeat instabil-
ity, this now poses the question as to whether FAN1
might act upon any of the more recently discovered
repeat expansion loci, and upon how many different
repeat sequence motifs FAN1 might act? [121, 122,
200, 201].
The mechanisms by which FAN1 may suppress
CAG or CGG repeat instability are unclear. Models
proposed [202, 203] include a) replication-associated
repeat instability, b) repair-associated repeat insta-
bility, and c) transcription-associated (R-loop) repeat
instability (Fig. 6). That FAN1 can affect CAG insta-
bility in post mitotic cells argues against a role of
FAN1 in instability at replication forks. The com-
mon ground for all these models is aberrant DNA
structures formed by the expanded sequence, called
slipped-DNAs, as intermediates of the expanded
mutations [202, 204, 205]. Unusual non-B-DNA
structures can form in vitro and in vivo at each of the
unstable repeats (reviewed in [205–210]). In addition,
all models of repeat instability require nucleases to
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Fig. 6. Possible roles of FAN1 in processing repeat-containing DNA, protecting against repeat instability. (a) Replication-associated repeat
instability; FAN1 may process slip-outs formed on a template or nascent strand during replication and may stabilize repeat length or induce
contraction. (b) A slip-out formed by repeat-containing DNA can be processed by a non-mitotic DNA repair associated mechanism. FAN1
may act as one of the critical nucleases to process repeat slip-outs to stabilize the repeat tract against length variations. (c) In non-replicating
cells, repeat instability is associated with active transcription across the expanded repeat. FAN1 may process the slip-outs formed following
unidirectional or bidirectional transcription across the expanded repeat, to stabilize repeat tract against length variations.
process the slipped-DNA and thus protect the repeat
tract from further expansion. Various DNA repair
endo- and exo-nucleases have been studied with
respect to repeat instability, such as FEN1, EXO1,
MutL and MutL [186, 202, 211–213]. Nonethe-
less, FAN1 is genetically implicated as a critical
nuclease involved in repeat instability, yet the exact
role of FAN1 nuclease in processing slipped-DNAs
formed by repeat tracts is still unexplored (see Section
4.4 for details).
7.3. Role of FAN1 in replication-associated
repeat instability
The replication-associated repeat instability model
[202, 214–216] suggests that during replication
of repeat-containing DNA, slip-out may form on
nascent or template DNA [202]. The slip-out on
nascent DNA may lead to expansions by re-repli-
cation, whereas that on template DNA leads to con-
traction [217, 218] (Fig. 6a). Possibly an unknown
nuclease processes the slip-out formed on nascent
DNA, protecting it from expansion. With both endo-
and exo-nuclease activity on structured DNA, FAN1
could perhaps fill this role.
The slip-out formed on the template strand may
cause replication machinery to pause and allow dis-
sociation of the replisome from the replication fork
[202, 219, 220]. However, the lagging strand contin-
uously synthesizes DNA, resulting in fork reversal
(Fig. 6a). FAN1 may be involved in the TLS pathway
and may process stalled replication forks (discussed
in Section 3), protecting it from repeat instability. The
recruitment of FAN1 to slipped-DNA following fork
stalling has yet to be proven.
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7.4. Role of FAN1 in repair-associated repeat
instability
In HD patients, tissue-specific expansion-biased
repeat instability is observed mainly in the brain and
liver [154, 221]. However, brain neuronal cells do not
undergo active replication, suggesting that somatic
repeat instability is not limited to DNA replication,
but may be induced by DNA repair mechanisms.
Expression of FAN1 is high in brain cells, supporting
its possible role in protecting against repeat insta-
bility. It is an interacting partner of MMR proteins,
notably MLH1 [4, 5, 7, 34, 43], suggesting that it
may be involved in MMR. Knowing how disruption
of the FAN1-MLH1 interaction affects the severity
of repeat expansion could be relevant to prediction of
the onset of neurological disorders.
The requirement of MMR complexes—including
MutS (MSH2-MSH3), MutS (MSH2-MSH6),
MutL (MLH1-PMS2) and MutL (MLH1-
MLH3)—in CAG/CTG, CGG/CCG, and GAA/TTC
repeat instability has been extensively studied
[185, 210, 213, 222–229]. MustS (MSH2-MSH3),
through its ability to bind slip-DNA structures, may
facilitate their formation [210]. MustS recruits
MutL complexes (Fig. 6b). MutL has endo-
nuclease activity on both the slipped-out and non-
slipped-out strands, in unnicked DNA [186, 230].
In contrast, MutL endo-nuclease cleaves only the
non-slipped-out strand [186]. MutL or MutL
generate a nick in the slip-out, potentially serving as
an entry point for exo-nucleases like EXO1 or FAN1,
both known to interact with MLH1 [231–233].
Any of these proteins may subsequently process
the slip-out and stabilize the repeat expansion. In
contrast, cleavage on the non-slip-out strand by
MutL may lead to WRN-RPA-mediated melting of
hairpin DNA [234]. Resulting gaps in the DNA may
be filled by DNA polymerase , which may lead
to repeat expansion [166, 186, 234, 235] (Fig. 6b).
FAN1 co-localizes with RPA at stalled replication
forks in cells [236] and the nuclease activity of FAN1
is enhanced by RPA [237], but a direct interaction
was not tested.
7.5. Role of FAN1 in transcription-associated
repeat instability
In non-replicating cells, repeat instability can be
driven by active transcription through the expanded
repeat. Transcription of repeat-containing DNA leads
to the formation of DNA:RNA hybrids, commonly
referred to as ‘R-loops’ (Fig. 6c). Slip-out struc-
tures may then form on the non-transcribed strand.
Bidirectional transcription may lead to the formation
of slip-outs in both strands [203, 238–241], which
are recognized by MutS and activate MutL com-
plexes. As with repair-associated repeat stability, the
relative contribution of MutL or MutL will deter-
mine the fate of the slip-out, giving rise to either
expansions, contractions, or stability. Repair of only
non-transcribing slip-outs may result in repeat expan-
sions, whereas repair of both slip-outs may lead
to repeat stability [203, 210, 238–241] (Fig. 6c).
However, for repair to happen, the slipped-DNA is
processed by DNA nucleases: an aspect that needs to
be further explored. In summary, it is possible that
FAN1, through its endo- and/or exo-nuclease activ-
ity, is involved in the processing of these slip-outs,
thereby protecting against further repeat expansion.
8. CONCLUSIONS AND FUTURE
PERSPECTIVES
FAN1 was initially thought to be associated
with Fanconi anemia (FA); however, rather than
FA, homozygous loss of FAN1 causes karyome-
galic interstitial nephritis (KIN) [31, 45]. Most KIN
mutations ablate nuclease activity of the enzyme,
indicating that this activity protects normal kidney
function [31]. Nuclease-defective FAN1 causes mild
hypersensitivity to DNA crosslinking agents in cells
and in mice, suggesting defects in ICL processing
[31]. FAN1 can process ICLs in an FA-independent
manner [29]. Its function in ICL repair and replication
fork-protection might be responsible for safeguard-
ing cells from endogenous and exogenous insults,
including platinum-based and mitomycin C-based
anti-cancer therapies. Loss of FAN1 function does
not increase the burden of human cancers [85]. Con-
sidering that some cytotoxic anticancer agents act by
inducing ICLs and/or replication stress, FAN1 nucle-
ase activity is likely a good target for sensitization of
cancer cells to killing by conventional chemotherapy.
However, this might not be applicable to HD subjects
who display lower cancer incidence than age- and
sex-matched controls [242].
FAN1 is the strongest modifier in HD [14, 15].
Increased FAN1 expression and DNA binding may
protect against somatic repeat expansion of trinu-
cleotide repeats [12, 14, 141]. However, the full set
of FAN1 functions—including the biochemistry of its
DNA binding activity, dimerization, nuclease activ-
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ities, various interaction partners, and roles in DNA
replication and repair—need further investigation,
particularly with regard to repeat DNAs. How this
diverse set of DNA metabolizing functions may con-
tribute to FAN1’s involvement in multiple diseases
is now a key focus. Variants in FAN1 contribute to
numerous diseases (including autism, schizophrenia,
and epilepsy), some of which are caused by expanded
repeat DNAs [20, 25, 122, 200, 201]. Current genetic
analysis supports a role of ongoing somatic repeat
expansions, play a role in the age-of-onset and pro-
gression rate of many such diseases. Regulation of
CAG/CTG and CGG/CCG repeats by FAN1 opens
the possibility that it may be involved with other
unstable repeat motifs associated with disorders such
as autism or schizophrenia [121, 122, 200, 201]. A
focus on elucidating the mechanistic role of FAN1 in
repeat instability is warranted, to learn if and how
it modifies disease by modulating somatic repeat
instability.
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[177] Schärer OD. XPG: Its products and biological roles. Adv
Exp Med Biol. 2008;637:83-92.
[178] Han C, Huang X, Hua R, Song S, Lyu L, Ta N, et al. The
association between XPG polymorphisms and cancer sus-
ceptibility: Evidence from observational studies. Medicine
(Baltimore). 2017;96(32):e7467.
[179] Notarangelo LD, Kim MS, Walter JE, Lee YN. Human
RAG mutations: Biochemistry and clinical implications.
Nat Rev Immunol. 2016;16(4):234-46.
[180] Mittelman D, Moye C, Morton J, Sykoudis K, Lin Y, Car-
roll D, et al. Zinc-finger directed double-strand breaks
within CAG repeat tracts promote repeat instability in
human cells. Proc Natl Acad Sci U S A. 2009;106(24):
9607-12.
[181] Syed A, Tainer JA. The MRE11-RAD50-NBS1 Complex
conducts the orchestration of damage signaling and out-
A.L. Deshmukh et al. / FAN1, a DNA Repair Nuclease, as a Modifier of Repeat Expansion Disorders 121
comes to stress in DNA replication and repair. Annu Rev
Biochem. 2018;87:263-94.
[182] Itan Y, Shang L, Boisson B, Patin E, Bolze A, Moncada-
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